

Medicare Medical Policy

Bone Growth Stimulators

MEDICARE MEDICAL POLICY NUMBER: 226

Effective Date: 10/1/2026

Last Review Date: 9/2026

Next Annual Review: 9/2027

MEDICARE COVERAGE CRITERIA	2
POLICY CROSS REFERENCES	2
POLICY GUIDELINES	3
REGULATORY STATUS.....	3
BILLING GUIDELINES AND CODING	3
REFERENCES	4
POLICY REVISION HISTORY	4

INSTRUCTIONS FOR USE: Company Medicare Medical Policies serve as guidance for the administration of plan benefits and do not constitute medical advice nor a guarantee of coverage. Company Medicare Medical Policies are reviewed annually to guide the coverage or non-coverage decision-making process for services or procedures in accordance with member benefit contracts (otherwise known as Evidence of Coverage or EOCs) and Centers of Medicare and Medicaid Services (CMS) policies, manuals, and other CMS rules and regulations. In the absence of a CMS coverage determination or specific regulation for a requested service, item or procedure, Company policy criteria or applicable utilization management vendor criteria may be applied. These are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

The Company reserves the right to determine the application of Medicare Medical Policies and make revisions to these policies at any time. Any conflict or variance between the EOC and Company Medical Policy will be resolved in favor of the EOC.

SCOPE: Providence Health Plan, Providence Health Assurance, and Providence Plan Partners as applicable (referred to individually as “Company” and collectively as “Companies”).

PRODUCT AND BENEFIT APPLICATION

☒ Medicare Only

MEDICARE COVERAGE CRITERIA

IMPORTANT NOTE: More than one Centers for Medicare and Medicaid Services (CMS) reference may apply to the same health care service, such as when more than one coverage policy is available (e.g., both an NCD and LCD exist). All references listed should be considered for coverage decision-making. The Company uses the most current version of a Medicare reference available at the time of publication; however, these websites are not maintained by the Company, so Medicare references and their corresponding hyperlinks may change at any time. If there is a conflict between the Company Medicare Medical Policy and CMS guidance, the CMS guidance will govern.

Service	Medicare Guidelines
<i>Osteogenic Stimulators – Noninvasive</i>	- National Coverage Determination (NCD): Osteogenic Stimulators (150.2) - Local Coverage Determination (LCD): Osteogenesis Stimulators (L33796) NOTE: For definitions of “multiple level fusion” or “multilevel spinal fusion” and “long bone”, please see the “Appendices” found in durable medical equipment Medicare contractor (DME MAC) LCD L33796.
<i>Osteogenic Stimulators – Invasive</i>	NCD: Osteogenic Stimulators (150.2) NOTE: The above LCD only applies to noninvasive stimulators. Since HCPCS code E0749 is used to report for a surgically implanted stimulator, the above DME MAC LCD does not apply to this item, nor to physician services to either implant the stimulator device or administer the electrical stimulation from these devices in the office.

IMPORTANT NOTICE: While some services or items may appear medically indicated for an individual, they may also be a direct exclusion of Medicare or the member’s benefit plan. Such excluded services or items by Medicare and member EOCs include, but are not limited to, services or procedures considered to be cosmetic, not medical in nature, or those considered not medically reasonable or necessary under *Title XVIII of the Social Security Act, §1862(a)(1)(A)*. If there is uncertainty regarding coverage of a service or item, please review the member EOC or submit a pre-service organization determination request. Note that the Medicare Advance Beneficiary Notice of Noncoverage (ABN) form **cannot** be used for Medicare Advantage members. (*Medicare Advance Written Notices of Non-coverage. MLN006266 May 2021*)

POLICY CROSS REFERENCES

None

The full Company portfolio of Medicare Medical Policies is available online and can be [accessed here](#).

POLICY GUIDELINES

None

REGULATORY STATUS

U.S. FOOD & DRUG ADMINISTRATION (FDA)

While clearance by the Food and Drug Administration (FDA) is a prerequisite for Medicare coverage, the 510(k) premarket clearance process does not in itself establish medical necessity. Medicare payment policy is determined by the interaction of numerous requirements, including but not limited to, the availability of a Medicare benefit category and other statutory requirements, coding and pricing guidelines, as well as national and local coverage determinations and clinical evidence.

BILLING GUIDELINES AND CODING

GENERAL

See associated local coverage articles (LCAs) for related billing and coding guidance:

- Local Coverage Article (LCA): Osteogenesis Stimulators- Policy Article ([A52513](#))

Bone growth stimulation is utilized to promote bone healing in difficult to heal fractures or fusions by applying electrical or ultrasonic current to the fracture/fusion site. Electrical stimulation can be applied either from the outside of the body (noninvasive) or from the inside of the body (invasive, or surgically implanted). Some bone growth stimulators, also known as osteogenic stimulators, may be considered durable medical equipment (DME), while others are not.

- If electrical stimulation used to aid bone healing is applied by a physician, bone stimulation codes (CPT codes 20974-20975) may be reported.¹
- If the bone stimulator device is provided to the member for use at home², then DME codes (E0747, E0748, E0760) would be used.

Table 1: Coding Guidelines for Bone Growth (Osteogenic) Stimulators

BODY REGION	TYPE	CPT/HCPCS CODING		NOTES
		Physician	DME (Home)	
Spinal	<i>Noninvasive (nonoperative)</i>	20974	E0748	- Codes for CPT codes for physician use are not specific to spinal or non-spinal regions. - HCPCS codes E0749 and E0760 are also not specific to spinal or non-spinal regions.
	<i>Invasive (Operative)</i>	20975, E0749	N/A	
	<i>Ultrasonic</i>	20979	E0760, A4559*	
Non-Spinal	<i>Noninvasive (nonoperative)</i>	20974	E0747	
	<i>Invasive (Operative)</i>	20975, E0749	N/A	
	<i>Ultrasonic</i>	20979	E0760, A4559*	

*Ultrasound conductive coupling gel (A4559) may only be eligible for coverage for Medicare Advantage members and separately payable if an ultrasonic osteogenesis stimulator is considered medically necessary.

CODES*		
CPT	20974	Electrical stimulation to aid bone healing; noninvasive (nonoperative)
	20975	Electrical stimulation to aid bone healing; invasive (operative)
	20979	Low intensity ultrasound stimulation to aid bone healing, noninvasive (nonoperative)
HCPCS	A4559	Coupling gel or paste, for use with ultrasound device, per oz
	E0747	Osteogenesis stimulator, electrical, non-invasive, other than spinal applications
	E0748	Osteogenesis stimulator, electrical, non-invasive, spinal applications
	E0749	Osteogenesis stimulator, electrical, surgically implanted
	E0760	Osteogenesis stimulator, low intensity ultrasound, non-invasive

***Coding Notes:**

- The code list above is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit. According to Medicare, “presence of a payment amount in the MPFS and the Medicare physician fee schedule database (MPFSDB) does not imply that CMS has determined that the service may be covered by Medicare.” The issuance of a CPT or HCPCS code or the provision of a payment or fee amount by Medicare does **not** make a procedure medically reasonable or necessary or a covered benefit by Medicare. (*Medicare Claims Processing Manual, Chapter 23 - Fee Schedule Administration and Coding Requirements, §30 - Services Paid Under the Medicare Physician’s Fee Schedule, A. Physician’s Services*)
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.
- See the non-covered and prior authorization lists on the Company [Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website](#) for additional information.
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

REFERENCES

- Centers for Medicare and Medicaid Services (CMS). National Correct Coding Initiative (NCCI) Policy Manual. Chapter 4, I. General Policy Statements. Updated 2026.
<https://www.cms.gov/medicare/coding-billing/national-correct-coding-initiative-ncci-edits/medicare-ncci-policy-manual>. Last Accessed 7/15/2026.
- Noridian DME Jurisdiction D. Place of Service. 2/22/2024.
<https://med.noridianmedicare.com/web/jddme/claims-appeals/claim-submission/pos>. Last Accessed 7/15/2026.

POLICY REVISION HISTORY

DATE	REVISION SUMMARY
------	------------------

10/2022	Annual review (converted to new format 2/2023)
10/2023	Annual review; no changes
10/2024	Annual review; divided criteria between “invasive” and “noninvasive” techniques – no change to criteria sources
1/2025	Interim update; no change to criteria
10/2025	Annual review; no change to criteria
10/2026	Annual review; no change to criteria